The trial will test four dose levels and include up to 18 patients with advanced, FLT3-expressing acute myeloid leukemia.

The firm aims to use its platform to guide selection of personalized and immunotherapies for cancer patients and to support drug development.

Pfizer opted to discontinue the product for "several reasons," including limited interest from patients and physicians in gene therapies for hemophilia.

The firm will test additional doses and use its proprietary drug response predictor to gather data that can inform a registrational study.

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

The biotech has met with UK regulators to discuss a marketing authorization application under exceptional circumstances based on data from 11 patients.

The firm plans to build on its organ and tissue modeling technology to develop more sophisticated tests, including full-body digital twins.

Blincyto plus chemo was approved for adult patients with Ph-negative, CD19-positive, and MRD-negative B-cell precursor acute lymphoblastic leukemia.

Bluebird Bio has commercialized three gene therapy products, including one of the first for sickle cell disease, but would soon run out of cash.

In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.